50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,711.61 (+1.55%)
DOW   29,629.20 (+1.26%)
QQQ   277.80 (+1.25%)
AAPL   152.70 (+1.28%)
MSFT   240.05 (+1.09%)
META   137.85 (+1.09%)
GOOGL   99.12 (+0.97%)
AMZN   117.20 (+1.78%)
TSLA   283.64 (+2.76%)
NVDA   124.73 (+2.00%)
NIO   18.15 (+3.01%)
BABA   79.28 (+0.47%)
AMD   67.59 (+1.95%)
T   15.78 (+0.70%)
MU   49.68 (+1.64%)
CGC   2.83 (+3.28%)
F   12.18 (+1.58%)
GE   65.50 (+1.79%)
DIS   99.50 (+1.41%)
AMC   7.17 (+4.98%)
PYPL   85.27 (+1.20%)
PFE   44.00 (+0.39%)
NFLX   228.60 (+2.02%)
S&P 500   3,711.61 (+1.55%)
DOW   29,629.20 (+1.26%)
QQQ   277.80 (+1.25%)
AAPL   152.70 (+1.28%)
MSFT   240.05 (+1.09%)
META   137.85 (+1.09%)
GOOGL   99.12 (+0.97%)
AMZN   117.20 (+1.78%)
TSLA   283.64 (+2.76%)
NVDA   124.73 (+2.00%)
NIO   18.15 (+3.01%)
BABA   79.28 (+0.47%)
AMD   67.59 (+1.95%)
T   15.78 (+0.70%)
MU   49.68 (+1.64%)
CGC   2.83 (+3.28%)
F   12.18 (+1.58%)
GE   65.50 (+1.79%)
DIS   99.50 (+1.41%)
AMC   7.17 (+4.98%)
PYPL   85.27 (+1.20%)
PFE   44.00 (+0.39%)
NFLX   228.60 (+2.02%)
S&P 500   3,711.61 (+1.55%)
DOW   29,629.20 (+1.26%)
QQQ   277.80 (+1.25%)
AAPL   152.70 (+1.28%)
MSFT   240.05 (+1.09%)
META   137.85 (+1.09%)
GOOGL   99.12 (+0.97%)
AMZN   117.20 (+1.78%)
TSLA   283.64 (+2.76%)
NVDA   124.73 (+2.00%)
NIO   18.15 (+3.01%)
BABA   79.28 (+0.47%)
AMD   67.59 (+1.95%)
T   15.78 (+0.70%)
MU   49.68 (+1.64%)
CGC   2.83 (+3.28%)
F   12.18 (+1.58%)
GE   65.50 (+1.79%)
DIS   99.50 (+1.41%)
AMC   7.17 (+4.98%)
PYPL   85.27 (+1.20%)
PFE   44.00 (+0.39%)
NFLX   228.60 (+2.02%)
S&P 500   3,711.61 (+1.55%)
DOW   29,629.20 (+1.26%)
QQQ   277.80 (+1.25%)
AAPL   152.70 (+1.28%)
MSFT   240.05 (+1.09%)
META   137.85 (+1.09%)
GOOGL   99.12 (+0.97%)
AMZN   117.20 (+1.78%)
TSLA   283.64 (+2.76%)
NVDA   124.73 (+2.00%)
NIO   18.15 (+3.01%)
BABA   79.28 (+0.47%)
AMD   67.59 (+1.95%)
T   15.78 (+0.70%)
MU   49.68 (+1.64%)
CGC   2.83 (+3.28%)
F   12.18 (+1.58%)
GE   65.50 (+1.79%)
DIS   99.50 (+1.41%)
AMC   7.17 (+4.98%)
PYPL   85.27 (+1.20%)
PFE   44.00 (+0.39%)
NFLX   228.60 (+2.02%)
NASDAQ:ARDX

Ardelyx - ARDX Stock Forecast, Price & News

$1.15
+0.02 (+1.77%)
(As of 09/27/2022 08:13 AM ET)
Add
Compare
Today's Range
$1.15
$1.15
50-Day Range
$0.67
$1.44
52-Week Range
$0.49
$1.92
Volume
10 shs
Average Volume
4.60 million shs
Market Capitalization
$177.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.33

Ardelyx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
283.5% Upside
$4.33 Price Target
Short Interest
Healthy
5.24% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.98
Upright™ Environmental Score
News Sentiment
0.62mentions of Ardelyx in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$37,034 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.70) to ($0.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

731st out of 1,071 stocks

Pharmaceutical Preparations Industry

346th out of 531 stocks

ARDX stock logo

About Ardelyx (NASDAQ:ARDX) Stock

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

ARDX Stock News Headlines

Ardelyx (NASDAQ: ARDX)
Ardelyx to Participate in Upcoming Investor Conferences
Ardelyx, Inc. (ARDX)
See More Headlines
Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

ARDX Company Calendar

Last Earnings
8/04/2022
Today
9/27/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARDX
Employees
86
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.33
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+276.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-158,160,000.00
Net Margins
-2,594.88%
Pretax Margin
-2,594.71%

Debt

Sales & Book Value

Annual Sales
$10.10 million
Book Value
$0.73 per share

Miscellaneous

Free Float
145,358,000
Market Cap
$177.84 million
Optionable
Optionable
Beta
1.68

Key Executives

  • Mr. Michael G. RaabMr. Michael G. Raab (Age 57)
    Pres, CEO & Director
    Comp: $1.04M
  • Mr. Justin A. Renz CPA (Age 50)
    M.S.T., MBA, MST, CFO & Treasurer
    Comp: $623.7k
  • Ms. Elizabeth A. GrammerMs. Elizabeth A. Grammer (Age 58)
    Chief Legal & Admin. Officer and Sec.
    Comp: $623.7k
  • Mr. David P. Rosenbaum (Age 61)
    Chief Devel. Officer
    Comp: $645.4k
  • Mr. Robert C. BlanksMr. Robert C. Blanks (Age 62)
    Chief Regulatory Affairs & Quality Assurance Officer
    Comp: $590.8k
  • Mr. Robert Felsch
    Sr. VP of Fin. & Chief Accounting Officer
  • Ms. Kimia Keshtbod
    Mang. of Corp. Communications & Investor Relations
  • Ms. Karen Harrigan
    Sr. Director Market Devel.
  • Dan Pavicich
    Sr. Director of Market Devel.
  • Ms. Susan Rodriguez (Age 58)
    Chief Commercial Officer













ARDX Stock - Frequently Asked Questions

Should I buy or sell Ardelyx stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings
or view top-rated stocks.

What is Ardelyx's stock price forecast for 2022?

6 brokerages have issued 1-year price targets for Ardelyx's shares. Their ARDX share price forecasts range from $1.00 to $10.00. On average, they expect the company's stock price to reach $4.33 in the next twelve months. This suggests a possible upside of 283.5% from the stock's current price.
View analysts price targets for ARDX
or view top-rated stocks among Wall Street analysts.

How have ARDX shares performed in 2022?

Ardelyx's stock was trading at $1.10 at the beginning of 2022. Since then, ARDX shares have increased by 2.7% and is now trading at $1.13.
View the best growth stocks for 2022 here
.

When is Ardelyx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our ARDX earnings forecast
.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) announced its earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($0.19) EPS for the quarter, meeting analysts' consensus estimates of ($0.19). The biopharmaceutical company had revenue of $2.53 million for the quarter, compared to the consensus estimate of $0.62 million. Ardelyx had a negative trailing twelve-month return on equity of 191.74% and a negative net margin of 2,594.88%. During the same period in the prior year, the company earned ($0.45) earnings per share.

What other stocks do shareholders of Ardelyx own?
What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by a number of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (3.23%), Prosight Management LP (1.40%), Ikarian Capital LLC (1.09%), Millennium Management LLC (1.00%), Sio Capital Management LLC (0.45%) and State Street Corp (0.31%). Insiders that own company stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Jeffrey W Jacobs, Justin A Renz, Mark Kaufmann, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends
.

How do I buy shares of Ardelyx?

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $1.13.

How much money does Ardelyx make?

Ardelyx (NASDAQ:ARDX) has a market capitalization of $174.74 million and generates $10.10 million in revenue each year. The biopharmaceutical company earns $-158,160,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The official website for the company is www.ardelyx.com. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at investor@ardelyx.com, or via fax at 510-745-0493.

This page (NASDAQ:ARDX) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.